Stoke Therapeutics Gestione
Criteri Gestione verificati 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Ian Smith
Amministratore delegato
US$27.0m
Compenso totale
| Percentuale dello stipendio del CEO | 0.63% |
| Mandato del CEO | 1.4yrs |
| Proprietà del CEO | n/a |
| Durata media del management | 1.4yrs |
| Durata media del Consiglio di amministrazione | 7.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Articolo di analisi • Aug 06
Analysts Have Made A Financial Statement On Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Second-Quarter Report
Investors in Stoke Therapeutics, Inc. ( NASDAQ:STOK ) had a good week, as its shares rose 8.3% to close at US$31.93...Seeking Alpha • Aug 05
Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement
Summary Stoke Therapeutics remains a "Buy," driven by progress on zorevunersen for SCN1A Dravet Syndrome and robust clinical milestones ahead. The company expects an FDA meeting in H2 2026, rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027 for zorevunersen. The advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study showcases the TANGO platform's broader therapeutic potential. Strong cash position, with a runway into early 2028, supports continued R&D and milestone execution across lead and pipeline programs. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 10
STOK: Phase 3 Dravet Data And NDA Timeline Will Drive Upside
Analysts have raised their fair value estimate for Stoke Therapeutics from $39.00 to $60.00, citing updated assumptions related to revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for Stoke Therapeutics Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome.
Aggiornamento narrativa • Jun 26
None
Analysts have lifted their price target for Stoke Therapeutics from $34.25 to $45.10, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple as key drivers of the change. What’s in the News for Stoke Therapeutics No recent company specific news for Stoke Therapeutics was identified in the provided sources.Articolo di analisi • May 11
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
Nuova narrativa • May 11
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Jan 12
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...Articolo di analisi • Dec 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...Articolo di analisi • Oct 09
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...Articolo di analisi • Aug 25
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...Articolo di analisi • Aug 15
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...Articolo di analisi • May 20
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Apr 16
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...Articolo di analisi • Apr 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...Articolo di analisi • Feb 26
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Feb 16
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking AlphaArticolo di analisi • Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...Articolo di analisi • Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$208m |
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$27m | US$171k | -US$7m |
| Sep 30 2025 | n/a | n/a | US$41m |
| Jun 30 2025 | n/a | n/a | US$52m |
| Mar 31 2025 | n/a | n/a | US$50m |
| Dec 31 2024 | US$248k | n/a | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$394k | n/a | -US$105m |
Compensazione vs Mercato: La retribuzione totale di Ian ($USD 27.03M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.12M ).
Compensazione vs guadagni: La retribuzione di Ian è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Ian Smith (60 yo)
1.4yrs
Mandato
US$27,031,655
Compensazione
Mr. Ian F. Smith, CPA, ACA, is CEO of Stoke Therapeutics, Inc. from October 6, 2025 and serves as its Director since September 19, 2023 and served as its Interim CEO from March 19, 2025 to October 6, 2025....
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$27.03m | Nessun dato | |
| Co-Founder & Independent Director | no data | US$268.34k | 0.44% $ 9.3m | |
| Chief Financial Officer | 2.3yrs | US$1.83m | 0.016% $ 332.6k | |
| Advisor & Director | 1.4yrs | US$3.23m | 0.17% $ 3.6m | |
| Chief Patient Officer | 2.3yrs | US$2.27m | 0.016% $ 336.2k | |
| Co-Founder & CTO | less than a year | Nessun dato | Nessun dato | |
| Chief Scientific Officer | less than a year | Nessun dato | Nessun dato | |
| Corporate Secretary | 5.5yrs | Nessun dato | 0.028% $ 591.6k | |
| Vice President of Corporate Communications | less than a year | Nessun dato | Nessun dato | |
| Chief People Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 8.8yrs | US$2.47m | 0.032% $ 668.0k | |
| Chief of Corporate Affairs & Strategic Partnerships | less than a year | Nessun dato | Nessun dato |
1.4yrs
Durata media
55.5yo
Età media
Gestione esperta: Il team dirigenziale di STOK non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | US$27.03m | Nessun dato | |
| Co-Founder & Independent Director | 12.2yrs | US$268.34k | 0.44% $ 9.3m | |
| Advisor & Director | 8.8yrs | US$3.23m | 0.17% $ 3.6m | |
| Independent Director | 11.1yrs | US$270.84k | 2.91% $ 61.3m | |
| Independent Director | 10.9yrs | US$281.25k | 0.034% $ 726.7k | |
| Independent Director | 6.2yrs | US$283.34k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$283.34k | 0% $ 0 | |
| Chairman of the Board | 7.9yrs | US$778.78k | 0.049% $ 1.0m | |
| Independent Director | less than a year | Nessun dato | Nessun dato |
7.9yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di STOK sono considerati esperti (durata media dell'incarico 7.9 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/10 20:31 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Stoke Therapeutics, Inc. è coperta da 22 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |